Phaseline

Companies › Lunan Better Pharmaceutical

Lunan Better Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 3; Respiratory, Ophthalmology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Formoterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 3Asthma (Diagnosis)Jun 2028
Lifitegrast
Integrin alpha-L/beta-2 (LFA-1) antagonist
ITGAL, ITGB2Phase 3Dry Eye Disease (DED)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06879782LifitegrastPhase 3Dry Eye Disease (DED)OphthalmologyMar 2026
NCT07768891FormoterolPhase 3Asthma (Diagnosis)RespiratoryJun 2028

Targets

ADRB2 (1) ITGAL (1) ITGB2 (1)

Companies with the same targets

Chiesi Farmaceutici AstraZeneca GSK Actimed Therapeutics ARS Pharmaceuticals Polarean Novartis EyeD Pharma Acer Therapeutics Teva Branded Pharmaceutical Products R&D

Companies built like this

Santen SAS Tecnoquimicas Neurotech Pharmaceuticals Innostellar Biotherapeutics Oorja Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.